Trevi Therapeutics Q2 EPS beats estimates
Trevi Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Trevi Therapeutics Inc - Expects Cash Resources To Fund Operations Into 2029
U.S. STOCKS ON THE MOVE-TransMedics, Centrus Energy, MongoDB
U.S. STOCKS ON THE MOVE-Boeing, GlobalFoundries, Tesla
U.S. STOCKS ON THE MOVE-Merus NV, Copper miners, GlobalFoundries
U.S. STOCKS ON THE MOVE-Trevi Therapeutics, Cactus, Copper miners
Trevi Therapeutics up after $100 mln equity raise
Brief: Trevi Therapeutics Announces Pricing Of $100 Million Underwritten Offering Of Common Stock
Trevi Therapeutics slips on $100 mln stock sale plans
Brief: Trevi Therapeutics Announces Proposed Public Offering Of Common Stock
Brief: Trevi Therapeutics Announces Positive Topline Results From Phase 2B Coral Trial Of Haduvio
Brief: Trevi Therapeutics Announces Additional Analyses From Phase 2A River Trial Of Haduvio In Patients With Refractory Chronic Cough
Trevi Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Trevi Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview
Trevi Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Avalo Therapeutics Appoints Michael Heffernan As Chairman Of The Board
Trevi Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Trevi Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview